A peptide Certificate of Analysis (COA) is the batch-specific lab report that documents identity, purity, and content for a given vial. The single most important first check is not the purity percentage: it is confirming that the product name and lot number on the COA match the vial in hand, that mass spectrometry evidence supports the expected identity, and that a chromatogram or spectra are actually attached rather than described secondhand.
TL;DR:
- Mass spectrometry data on the COA must include spectra linked to the specific lot, as simple mass confirmation does not verify peptide sequence.
- The chromatogram’s purity percentage is relative and should be interpreted alongside the chromatogram’s quality, method, and wavelength details for accuracy.
- Verify that the lot number on the COA matches the vial label, the lab is accredited, and raw spectra are available for true batch traceability.
- A complete COA must include identity proof, purity measurement, assay content, sample metadata, and supporting spectra or chromatograms.
- Combining multiple orthogonal methods like LC-MS/MS and NMR is recommended to detect impurities missed by HPLC alone.
Table of Contents
- What a COA typically contains: sections and metadata to expect
- Verifying identity on the COA: mass spectrometry evidence and limits
- Interpreting purity and chromatograms: what percent area means and what to inspect
- Assay and peptide content: converting COA data into usable concentrations
- Impurity profiling and orthogonal methods: when to request LC-MS/MS, NMR, or extra tests
- Red flags and verification checklist: how to spot weak or fraudulent COAs
- Batch traceability, reserve samples, and recordkeeping best practices
- Publisher COA practice: what Purity X Peptides provides
- What the checklist gets right and where it still falls short
- Where to download COAs and get technical support
- Sources
- FAQ
What a COA typically contains: sections and metadata to expect
A complete COA opens with a report header: product name, chemical form or salt, lot number, report date, and the testing lab’s name and contact information. Without this metadata, the document cannot be tied to a specific batch, which defeats its purpose.
Beyond the header, most reports include a defined set of analytical results:
- RP-HPLC chromatogram with a stated purity percentage at a specified wavelength
- LC-MS or MS/MS mass data confirming the molecular weight
- Assay or content value, often expressed as mg per vial
- Water content, counterion content, or residual solvent figures
- An impurities table listing detected related substances
- Sterility or endotoxin results, when the product and testing scope call for them
Each result depends on a method: the column, gradient, and detection wavelength used. According to peer-reviewed guidance on peptide characterization, orthogonal techniques including RP-HPLC, LC-MS, MS/MS, and NMR are recommended precisely because no single method covers identity, purity, and content at once. Reading the acceptance criteria alongside the raw result, rather than the result alone, is what separates a usable COA from a decorative one.
Verifying identity on the COA: mass spectrometry evidence and limits
Mass spectrometry on a COA typically reports one or more mass peaks that should align with the expected monoisotopic or average molecular weight of the peptide, allowing for common adducts such as sodium or potassium additions. A close match supports identity, but it only supports mass, not sequence.
Standard MS confirms that a molecule of the correct mass is present. Confirming that the amino acid sequence itself is correct requires MS/MS fragmentation or a comparable sequencing step. The same characterization guidance is clear that MS alone does not establish sequence identity unless MS/MS or sequencing data accompanies it, a distinction that matters most for novel or modified peptides where a mass-matched impurity could pass as the target compound.
A thorough COA includes the actual spectrum image or a downloadable file, the method identifiers used to generate it, and a clear link between that spectrum and the specific lot being reported. A summary line reading “MS confirmed” with no attached data leaves the identity claim unverifiable.
Interpreting purity and chromatograms: what percent area means and what to inspect
The purity percentage on an RP-HPLC chromatogram is a percent-area calculation: the target peak’s area divided by the total integrated area at a given detection wavelength. It is a relative measure, not an absolute one, and it says nothing about what fraction of the vial’s mass is actually peptide.
When reviewing the chromatogram itself, look for a single dominant peak with minimal tailing, no unexplained shoulders, and low baseline noise. Multiple close peaks or a poorly resolved baseline can indicate co-eluting impurities that a summary purity number will not reveal on its own. USP guidance on peptide reference standards notes that RP-HPLC purity is a relative chromatographic measure and does not by itself establish absolute mass, sterility, or endotoxin status.
Method details change the interpretation entirely. A purity figure generated at 214 nanometers on one column is not directly comparable to a figure from a different column or wavelength. When the method is missing from the report, request it before relying on the number.
Assay and peptide content: converting COA data into usable concentrations
A vial’s net powder weight and its actual peptide content are not the same figure. Water, counterions, and salt forms all add mass that is not peptide, so a 5 mg vial may contain meaningfully less than 5 mg of active peptide once these contributions are removed.
- Locate the assay or mg/vial value on the COA and confirm the basis it is reported on: as-is, anhydrous, or free-base.
- Use that assay value, not the nominal vial weight, as the peptide mass in any dilution calculation.
- When only a percent purity is given with no assay figure, apply mass-balance reasoning carefully and document every assumption made.
USP’s approach to purity assignment describes a mass-balance method that accounts for water and counterion content separately from HPLC purity, which is why the reporting basis has to travel with every number pulled from the COA. Reconstitution steps, including proper handling of BAC water, depend on getting this basis right before diluting to a target concentration.
Impurity profiling and orthogonal methods: when to request LC-MS/MS, NMR, or extra tests
A single HPLC trace can miss impurities that co-elute with the main peak or that share a nearly identical mass. Combining RP-HPLC with LC-MS/MS or NMR closes that gap, since each technique responds to a different physical property of the molecule.
FDA guidance on comparative impurity assessment for peptide products recommends assessing impurities across multiple batches, with defined thresholds for reporting and identifying related substances. Applied proportionately to research-grade material, the same logic holds: a trace impurity worth reporting is not automatically one that needs full identification, but sensitive studies benefit from asking.
When a study is particularly sensitive to trace variants, request impurity identification data, spiking experiments, or method validation records rather than accepting a summary percentage. Peer-reviewed discussion of orthogonal analytical approaches makes the same point: HPLC and MS alone can miss closely related impurities that only a combined method catches.
Red flags and verification checklist: how to spot weak or fraudulent COAs
Some COAs are incomplete by accident; others are templated documents with no real batch behind them. Either way, the warning signs look similar.
- No lot number, or a lot number that does not match the vial label
- No chromatogram or spectrum image, only a stated purity percentage
- Identical-looking reports across different products or dates
- A lab name or address that cannot be independently confirmed
- A report date that predates the product’s manufacture or sale
Before accepting a COA at face value, match the vial’s lot to the document, confirm the lab’s accreditation and testing scope under ISO/IEC 17025, and request the raw chromatogram or spectra files rather than a summary page. If anything remains unresolved, quarantine the material and ask for re-testing or an independent lab check before use.
Pro Tip: Keep the raw chromatogram file, not just the summary PDF; a re-integration by an independent lab is only possible when the original data trace is available.
Batch traceability, reserve samples, and recordkeeping best practices
Every COA used in a study should be logged with its version, lot number, and storage conditions, and the electronic PDF should be linked directly to the study record rather than stored separately. EDQM technical guidance on peptides recommends this kind of traceability and documented labelling as standard practice for reproducibility.
Retaining a small reserve sample from each lot, with a documented chain of custody, gives a lab the option to request re-analysis if a result is later questioned. Archiving the raw chromatogram and spectrum files alongside the COA, rather than relying on the summary alone, is what makes that re-analysis possible months or years later.
Publisher COA practice: what Purity X Peptides provides
Purity X Peptides provides batch-specific certificates of analysis for its research compounds, including downloadable COA documentation such as the Tirzepatide COA example, alongside COAs for BPC-157 and Ipamorelin. The same documentation standard applies to featured research compounds including MOTS-c 40mg, Melanotan II 10mg, and TB-500 10mg.
Each COA package is intended to include the chromatogram, assay value, and lot-specific metadata described throughout this article. Researchers who need raw chromatogram files, additional spectra, or method details beyond what is posted can contact technical support directly for that data. These materials are supplied for qualified research use only, and verification requests should reference the specific product and lot number in question.
What the checklist gets right and where it still falls short
The habit worth building is treating a COA as a set of linked claims, not a single grade. A researcher who reads only the purity percentage is trusting a relative chromatographic measurement to answer questions it was never designed to answer: sequence identity, sterility, and actual peptide mass all live in separate parts of the report.
Conventional advice tends to stop at “check the COA exists,” which is a low bar. The more useful habit is checking whether the COA’s individual pieces agree with each other: does the assay basis match the calculation being used, does the mass spec result correspond to the labeled lot, and is the chromatogram’s method actually stated. A COA with a clean-looking purity number and no method detail is less trustworthy than a slightly messier one that shows its work.
Prioritize traceability over polish. A lab that can produce raw spectra and lot-matched documentation on request is a better long-term source than one whose reports simply look tidy.
— Purity X Peptides
Where to download COAs and get technical support
Verifying a COA is only useful when the underlying documentation is actually available, which is why Purity X Peptides publishes batch-specific COAs for its research compounds rather than a single generic template.
Researchers working across metabolic, longevity, or recovery-focused studies can find COA-backed products directly through the relevant category pages:
- MOTS-c 40mg, Melanotan II 10mg, and TB-500 10mg each carry a downloadable, lot-specific COA
- Browse the Metabolic, Recovery and Repair, and Growth Hormone Pathways collections for related research compounds
- Visit the Certificate of Analysis page for details on how each COA is generated and what to request if raw chromatogram or spectra files are needed
All products and accompanying documentation are supplied strictly for qualified laboratory research use. For method details, raw data files, or lot-specific questions, contact technical support through the product page for the compound in question.
Sources
- Peptide characterization and orthogonal techniques (PMC)
- USP reference standards and peptide analytical guidance (USP)
- FDA guidance excerpt on comparative impurity assessment for peptide products (FDA)
- EDQM technical guidance on peptides and labelling (EDQM)
FAQ
What information should a peptide COA always report?
A complete COA reports identity evidence such as mass spectrometry data, a purity percentage from RP-HPLC with its chromatogram, and an assay or content value on a stated basis. Report metadata, including lot number, report date, and testing lab name, should also be present so the document can be tied to a specific batch.
Can a high purity percentage alone confirm a peptide is correct?
No. A purity percentage is a relative chromatographic measurement and does not by itself confirm sequence identity, sterility, or actual peptide mass, according to USP guidance on peptide reference standards. Identity requires separate mass spectrometry or sequencing evidence.
Why do some COAs include multiple analytical methods?
Orthogonal methods such as LC-MS/MS and NMR catch impurities that RP-HPLC or standard mass spectrometry alone can miss, particularly co-eluting or isomeric species. Peer-reviewed guidance on peptide characterization recommends combining these techniques rather than relying on a single result.
How can I verify a peptide COA is legitimate?
Match the lot number on the COA to the vial label, confirm the testing lab’s accreditation and scope, and request the raw chromatogram and spectra files rather than a summary page. If the lab cannot be independently confirmed or the documentation looks templated, treat the material as unverified and request re-testing.